<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658487</url>
  </required_header>
  <id_info>
    <org_study_id>VICC HEM 1553</org_study_id>
    <secondary_id>NCI-2015-01735</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02658487</nct_id>
  </id_info>
  <brief_title>Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia</brief_title>
  <acronym>VITAL</acronym>
  <official_title>Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well vosaroxin and cytarabine work in treating patients with
      untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and
      cytarabine, work in different ways to stop the growth of cancer cells, either by killing the
      cells, by stopping them from dividing, or by stopping them from spreading.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the rate of complete remission (CR) after induction therapy with the combination
      of &quot;7+V&quot; (vosaroxin and standard dose infusional cytosine arabinoside [ara-C]) for patients
      with newly diagnosed, previously untreated acute myelogenous leukemia (AML).

      SECONDARY OBJECTIVES:

      I. Frequency of grade 3-5 adverse events related to administration of &quot;7+V&quot;.

      II. To evaluate for the presence of minimal residual disease (MRD) remaining after &quot;7+V&quot;
      induction and/or re-induction.

      III. To determine the CR/CR with incomplete blood count recovery (CRi) rate after one and/or
      2 cycles of &quot;7+V&quot; induction.

      IV. To determine the time to neutrophil and platelet recovery following &quot;7+V&quot; induction.

      V. To assess disease-free survival (DFS) at 1 year (yr) of patients achieving CR/CRi after
      &quot;7+V&quot; induction.

      VI. To assess overall survival (OS) at 1 yr of all patients receiving protocol-defined
      therapy.

      VII. To determine the correlation of hematopoietic stem cell transplant (HSCT) comorbidity
      index and Wheatley Index scores with disease response, DFS and OS.

      TERTIARY OBJECTIVES:

        -  I. To describe the mutational burden of this cohort of AML patients.

        -  II. To correlate genomic aberration with response rate, DFS, and OS.

        -  III. To determine the number of patients treated with vosaroxin who eventually go to
           allogeneic HSCT.

      OUTLINE:

      Patients receive vosaroxin intravenously (IV) on days 1 and 4 and cytarabine IV continuously
      on days 1-7 (Induction-I). Patients with residual leukemia and for whom a second course is
      indicated in the judgment of the investigator may undergo a second course of treatment
      (Induction-II) 14-57 days after day 1 of Induction-1

      After completion of study treatment, patients are followed every 3 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission Rate (CR)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>CR is calculated as the percentage of patients with complete remission after the therapy. The response criteria is based on International Working Group Criteria. Complete Remission: Neutrophils(cells/μl)&gt;1000, Platelets (plt/μl)≥ 100,000,Bone marrow blasts (%) &lt;5; CR with incomplete count recovery (CRi): meets criteria for CR except for neutrophils ≤1000 or Meets criteria for CR except for platelets&lt; 100,000; Partial Remission: CR except for Bone marrow blasts (%) Decrease of ≥ 50% to value between 5% and 25%; Treatment Failure:Persistent acute myeloid leukemia in blood or bone marrow, or therapy fails to achieve a remission of any category, or death prior to response assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>From start of therapy up to 1 year</time_frame>
    <description>Survival distribution will be estimated using the method of Kaplan and Meier. Event-free survival time is defined as the time from start of therapy to progression or death for any reason (which ever comes first), and those alive without progression are censored at the last day of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Grade 3-5 Adverse Event Related to Cytarabine and Vosaroxin (7+V)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Counts of all events are summed up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free Survival (LFS or DFS)</measure>
    <time_frame>The time from complete remission to disease progression or death for any reason, assessed up to 1 year</time_frame>
    <description>Survival distribution will be estimated using the method of Kaplan and Meier. LFS time is defined as the time from complete remission to disease progression or death for any reason and those disease free and alive are censored at the last day of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The time from start of therapy to death, assessed up to 1 year</time_frame>
    <description>Survival distribution will be estimated using the method of Kaplan and Meier. The overall survival time is defined as time from start of therapy to death of any reason. Those alive are censored at the last day of known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Frequency of minimal residual disease (MRD) remaining after &quot;7+V&quot; induction and/or re-induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CR/CRi</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Frequency of Complete Remission / Complete Remission with Incomplete Count Recovery (CR/CRi) after &quot;7+V&quot; induction and/or re-induction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlate HSCT Comorbidity Index, Wheatley Index, and AML-Score Values With Disease Response</measure>
    <time_frame>Up to 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlate HSCT Comorbidity Index, Wheatley Index, and AML-Score Values With DFS</measure>
    <time_frame>The time from complete remission to disease progression or death for any reason, assessed up to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlate HSCT Comorbidity Index, Wheatley Index, and AML-Score Values With OS</measure>
    <time_frame>The time from start of therapy to death for any reason, assessed up to 1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia With Multilineage Dysplasia</condition>
  <condition>Myeloid Sarcoma</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Therapy-Related Acute Myeloid Leukemia</condition>
  <condition>Therapy-Related Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (vosaroxin, cytarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vosaroxin, cytarabine)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vosaroxin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vosaroxin, cytarabine)</arm_group_label>
    <other_name>AG-7352</other_name>
    <other_name>SNS-595</other_name>
    <other_name>SPC 595</other_name>
    <other_name>Voreloxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Ability to tolerate intensive therapy with vosaroxin 90 mg/m^2 and cytarabine

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 at time of study
             entry

          -  Morphologically confirmed new diagnosis of AML in accordance with World Health
             Organization (WHO) diagnostic criteria

          -  Patients who have received hydroxyurea alone or have previously received
             &quot;non-cytotoxic&quot; therapies for myelodysplastic syndromes (MDS) or myeloproliferative
             neoplasms (MPN) (e.g., thalidomide or lenalidomide, 5-azacytidine or decitabine,
             histone deacetylase inhibitors, low-dose Cytoxan, tyrosine kinase or dual tyrosine
             kinase [TK]/SRC proto-oncogene, non-receptor tyrosine kinase [src] inhibitors) will be
             allowed

          -  Serum creatinine =&lt; 2.0 mg/dL

          -  Hepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =&lt;
             2.5 x upper limit of normal

          -  Total bilirubin =&lt; 1.5 x upper limit of normal unless clearly related to Gilbert's
             disease, hemolysis or leukemic infiltrate

          -  FOR PATIENTS IN STAGE 1 (PATIENTS #1-#17)

          -  &gt;= 55 years of age with AML of any risk classification, or 18-54 years of age with
             high-risk AML disease based on one of the following:

               -  Antecedent hematologic disorder including myelodysplasia (MDS)-related AML
                  (MDS/AML) and prior myeloproliferative disorder (MPD)

               -  Treatment-related myeloid neoplasms (t-AML/t-MDS)

               -  AML with FLT3-ITD

               -  Myeloid sarcoma

               -  AML with multilineage dysplasia (AML-MLD)

               -  Adverse cytogenetics (defined as -5/-5q; -7/-7q; abnormal 3q, 9q, 11q, 20q, 21q
                  or 17p; t(6;9); t(9;22); trisomy 8; trisomy 13; trisomy 21; complex karyotypes
                  (&gt;= 3 clonal abnormalities); monosomal karyotypes

          -  FOR PATIENTS IN STAGE 2 (ENROLLED PATIENT #18 AND BEYOND)

          -  &gt;= 55 years of age with AML of any risk classification, or 18-54 years of age with
             intermediate or high risk AML as defined by National Comprehensive Cancer Network
             (NCCN) risk assignment

        Exclusion Criteria:

          -  STAGES 1 AND 2

          -  Patients with acute promyelocytic leukemia (APL) as diagnosed by morphologic criteria,
             flow cytometric characteristics, and rapid cytogenetics or fluorescence in situ
             hybridization (FISH) or molecular testing

          -  Any previous treatment with vosaroxin

          -  Concomitant chemotherapy, radiation therapy

               -  For patients with hyperleukocytosis with &gt; 50,000 blasts/μL; leukapheresis or
                  hydroxyurea may be used prior to study drug administration for cytoreduction at
                  the discretion of the treating physician

          -  Active, uncontrolled infection

               -  Patients with infection under active treatment and controlled with antibiotics,
                  antivirals, or antifungals are eligible

               -  Chronic hepatitis is acceptable

          -  Active, uncontrolled graft vs. host disease (GVHD) following allogeneic transplant for
             non-AML condition (e.g. MDS, lymphoid malignancy, aplastic anemia); patients with GVHD
             controlled on stable doses of immunosuppressants are eligible

          -  Presence of other life-threatening illness

          -  Left ventricular ejection fraction (LVEF) &lt; 40% as measured by echocardiogram or multi
             gated acquisition scan (MUGA)

          -  Known or suspected central nervous system (CNS) involvement of active AML

          -  Other active malignancies including other hematologic malignancies or other
             malignancies within 12 months before randomization, except nonmelanoma skin cancer or
             cervical intraepithelial neoplasia

          -  History of myocardial infarction (MI), unstable angina, cerebrovascular accident, or
             transient ischemic attack (CVA/TIA) within 3 months before randomization

          -  Prior or current therapy:

               -  Hydroxyurea or medications to reduce blast count within 24 hours before
                  randomization

               -  Treatment with an investigational product within 14 days before randomization, or
                  not recovered from all acute effects of previously administered investigational
                  products

          -  Renal insufficiency requiring hemodialysis or peritoneal dialysis

          -  Pregnant or breastfeeding

          -  Known human immunodeficiency virus (HIV) seropositivity

          -  Any other medical, psychological, or social condition that may interfere with study
             participation or compliance, or compromise patient safety in the opinion of the
             investigator or medical monitor

          -  ADDITIONAL EXCLUSION CRITERIA APPLIED TO STAGE 1

          -  Patients 18-54 years of age with &quot;good risk&quot; AML defined as the presence of t(8;21),
             inv(16), or t(16;16) as diagnosed by morphologic criteria, flow cytometric
             characteristics, and rapid cytogenetics or FISH

          -  Patients with t(8;21), inv(16), t(16;16) who are unable to receive anthracycline based
             induction will be allowed to enroll provided the medical reason they are unable to
             receive anthracyclines is clearly documented and provided they fulfill all other
             eligibility and criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Strickland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Savona, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <results_first_submitted>April 30, 2020</results_first_submitted>
  <results_first_submitted_qc>May 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Stephen Strickland</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Division of Hematology/Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Sarcoma, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02658487/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period for this trial was March 2016 to April 2019. Participants were recruited at Vanderbilt University Medical Center, Yale University, and University Medical School, South Carolina.</recruitment_details>
      <pre_assignment_details>42 participants met all eligibility criteria and were enrolled on this study. Nine of the participants received a second induction.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Vosaroxin, Cytarabine) Induction</title>
          <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure, circulating blasts</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refractory AML</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Vosaroxin, Cytarabine)</title>
          <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" lower_limit="33.4" upper_limit="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown/unreported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Remission Rate (CR)</title>
        <description>CR is calculated as the percentage of patients with complete remission after the therapy. The response criteria is based on International Working Group Criteria. Complete Remission: Neutrophils(cells/μl)&gt;1000, Platelets (plt/μl)≥ 100,000,Bone marrow blasts (%) &lt;5; CR with incomplete count recovery (CRi): meets criteria for CR except for neutrophils ≤1000 or Meets criteria for CR except for platelets&lt; 100,000; Partial Remission: CR except for Bone marrow blasts (%) Decrease of ≥ 50% to value between 5% and 25%; Treatment Failure:Persistent acute myeloid leukemia in blood or bone marrow, or therapy fails to achieve a remission of any category, or death prior to response assessment</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vosaroxin, Cytarabine)</title>
            <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Remission Rate (CR)</title>
          <description>CR is calculated as the percentage of patients with complete remission after the therapy. The response criteria is based on International Working Group Criteria. Complete Remission: Neutrophils(cells/μl)&gt;1000, Platelets (plt/μl)≥ 100,000,Bone marrow blasts (%) &lt;5; CR with incomplete count recovery (CRi): meets criteria for CR except for neutrophils ≤1000 or Meets criteria for CR except for platelets&lt; 100,000; Partial Remission: CR except for Bone marrow blasts (%) Decrease of ≥ 50% to value between 5% and 25%; Treatment Failure:Persistent acute myeloid leukemia in blood or bone marrow, or therapy fails to achieve a remission of any category, or death prior to response assessment</description>
          <population>Evaluable patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <description>Survival distribution will be estimated using the method of Kaplan and Meier. Event-free survival time is defined as the time from start of therapy to progression or death for any reason (which ever comes first), and those alive without progression are censored at the last day of follow up.</description>
        <time_frame>From start of therapy up to 1 year</time_frame>
        <population>All patients participated</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vosaroxin, Cytarabine)</title>
            <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival</title>
          <description>Survival distribution will be estimated using the method of Kaplan and Meier. Event-free survival time is defined as the time from start of therapy to progression or death for any reason (which ever comes first), and those alive without progression are censored at the last day of follow up.</description>
          <population>All patients participated</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="2.9" upper_limit="NA">insufficient number of participants with events for estimating</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Grade 3-5 Adverse Event Related to Cytarabine and Vosaroxin (7+V)</title>
        <description>Events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Counts of all events are summed up.</description>
        <time_frame>Up to 3 months</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vosaroxin, Cytarabine)</title>
            <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Grade 3-5 Adverse Event Related to Cytarabine and Vosaroxin (7+V)</title>
          <description>Events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Counts of all events are summed up.</description>
          <population>All participants</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leukemia-free Survival (LFS or DFS)</title>
        <description>Survival distribution will be estimated using the method of Kaplan and Meier. LFS time is defined as the time from complete remission to disease progression or death for any reason and those disease free and alive are censored at the last day of follow up.</description>
        <time_frame>The time from complete remission to disease progression or death for any reason, assessed up to 1 year</time_frame>
        <population>Patients who had complete remission after the therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vosaroxin, Cytarabine)</title>
            <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Leukemia-free Survival (LFS or DFS)</title>
          <description>Survival distribution will be estimated using the method of Kaplan and Meier. LFS time is defined as the time from complete remission to disease progression or death for any reason and those disease free and alive are censored at the last day of follow up.</description>
          <population>Patients who had complete remission after the therapy</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="13.1" upper_limit="NA">the median and upper bound are not estimable due to not long enough follow up</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Survival distribution will be estimated using the method of Kaplan and Meier. The overall survival time is defined as time from start of therapy to death of any reason. Those alive are censored at the last day of known alive.</description>
        <time_frame>The time from start of therapy to death, assessed up to 1 year</time_frame>
        <population>All participated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vosaroxin, Cytarabine)</title>
            <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survival distribution will be estimated using the method of Kaplan and Meier. The overall survival time is defined as time from start of therapy to death of any reason. Those alive are censored at the last day of known alive.</description>
          <population>All participated patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="7.4" upper_limit="NA">insufficient number of participants with events for estimating the upper bound</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimal Residual Disease</title>
        <description>Frequency of minimal residual disease (MRD) remaining after &quot;7+V&quot; induction and/or re-induction</description>
        <time_frame>Up to 3 months</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of CR/CRi</title>
        <description>Frequency of Complete Remission / Complete Remission with Incomplete Count Recovery (CR/CRi) after &quot;7+V&quot; induction and/or re-induction</description>
        <time_frame>Up to 3 months</time_frame>
        <population>Evaluable patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vosaroxin, Cytarabine)</title>
            <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
Cytarabine: Given IV
Vosaroxin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of CR/CRi</title>
          <description>Frequency of Complete Remission / Complete Remission with Incomplete Count Recovery (CR/CRi) after &quot;7+V&quot; induction and/or re-induction</description>
          <population>Evaluable patients</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.40" upper_limit="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlate HSCT Comorbidity Index, Wheatley Index, and AML-Score Values With Disease Response</title>
        <time_frame>Up to 3 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlate HSCT Comorbidity Index, Wheatley Index, and AML-Score Values With DFS</title>
        <time_frame>The time from complete remission to disease progression or death for any reason, assessed up to 1 year</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlate HSCT Comorbidity Index, Wheatley Index, and AML-Score Values With OS</title>
        <time_frame>The time from start of therapy to death for any reason, assessed up to 1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events that emerge (or worsen) after the first dose of study drug and within 30 days after the last dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Vosaroxin, Cytarabine) Induction 1</title>
          <description>Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I).
Cytarabine: Given IV
Vosaroxin: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Induction 2</title>
          <description>Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE V4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute sigmoid diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fungemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event - Related to Hickman line placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE V4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="27" subjects_at_risk="33"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="33"/>
                <counts group_id="E2" events="19" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="20" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia/multiorgan failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Concern for fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Staph bacteremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="36" subjects_affected="17" subjects_at_risk="33"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="55" subjects_affected="21" subjects_at_risk="33"/>
                <counts group_id="E2" events="20" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E2" events="16" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Worsening Platelet Count Decrease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter related thorombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Strickland, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>(615) 936-8422</phone>
      <email>stephen.strickland@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

